AU2008208151B2 - Topical formulation - Google Patents

Topical formulation Download PDF

Info

Publication number
AU2008208151B2
AU2008208151B2 AU2008208151A AU2008208151A AU2008208151B2 AU 2008208151 B2 AU2008208151 B2 AU 2008208151B2 AU 2008208151 A AU2008208151 A AU 2008208151A AU 2008208151 A AU2008208151 A AU 2008208151A AU 2008208151 B2 AU2008208151 B2 AU 2008208151B2
Authority
AU
Australia
Prior art keywords
composition
combinations
formulation
drug
methimazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008208151A
Other languages
English (en)
Other versions
AU2008208151A1 (en
Inventor
Fadil Al Alawi
Paul Chambers
Kate Hill
Karthigeyan Nanjan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elanco New Zeeland
Original Assignee
Elanco New Zeeland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco New Zeeland filed Critical Elanco New Zeeland
Publication of AU2008208151A1 publication Critical patent/AU2008208151A1/en
Assigned to BAYER NEW ZEALAND LIMITED reassignment BAYER NEW ZEALAND LIMITED Alteration of Name(s) of Applicant(s) under S113 Assignors: BOMAC RESEARCH LIMITED
Application granted granted Critical
Publication of AU2008208151B2 publication Critical patent/AU2008208151B2/en
Assigned to Elanco New Zealand reassignment Elanco New Zealand Request for Assignment Assignors: BAYER NEW ZEALAND LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008208151A 2007-01-24 2008-01-22 Topical formulation Active AU2008208151B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ552816A NZ552816A (en) 2007-01-24 2007-01-24 Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof
NZ552816 2007-01-24
PCT/NZ2008/000011 WO2008091167A1 (en) 2007-01-24 2008-01-22 Topical formulation

Publications (2)

Publication Number Publication Date
AU2008208151A1 AU2008208151A1 (en) 2008-07-31
AU2008208151B2 true AU2008208151B2 (en) 2014-02-20

Family

ID=39644688

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008208151A Active AU2008208151B2 (en) 2007-01-24 2008-01-22 Topical formulation

Country Status (7)

Country Link
US (1) US8748467B2 (enExample)
EP (1) EP2124938A4 (enExample)
JP (1) JP2010516761A (enExample)
AU (1) AU2008208151B2 (enExample)
CA (1) CA2713199C (enExample)
NZ (1) NZ552816A (enExample)
WO (1) WO2008091167A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552816A (en) 2007-01-24 2009-05-31 Bomac Research Ltd Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof
JP5827954B2 (ja) * 2010-09-30 2015-12-02 富山化学工業株式会社 経皮吸収製剤
CA3186350A1 (en) * 2013-02-27 2014-09-04 Argenta Innovation Limited Transdermal formulations
CN106714794B (zh) 2014-05-13 2021-05-11 登卓药物有限公司 用于治疗甲状腺功能亢进的制剂
WO2016198472A1 (en) 2015-06-09 2016-12-15 Hpf Ip Holding S.A. Topical delivery system
WO2018195411A1 (en) * 2017-04-21 2018-10-25 Steven Hoffman Compositions and methods for treating retinopathy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122472A1 (fr) * 2005-05-18 2006-11-23 Ling Chen Onguent antithyroïdien à usage externe et préparation de celui-ci

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296222A (en) * 1989-02-23 1994-03-22 University Of Utah Percutaneous drug delivery system
US5091182A (en) * 1990-07-23 1992-02-25 Syntex (U.S.A.) Inc. Dispensing units for ketorolac topical gel formlations
EP0702554A1 (en) * 1993-06-07 1996-03-27 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection
CN1046089C (zh) 1993-07-24 1999-11-03 陈凌 外敷用抗甲状腺乳膏
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
IL127189A0 (en) * 1996-05-22 1999-09-22 Diversified Pharmaceuticals In Compositions methods and devices for the transdermal delivery of drugs
WO1998003641A1 (en) * 1996-07-23 1998-01-29 Crandall Wilson T Transdermal transport of molecules
US5919436A (en) * 1997-09-25 1999-07-06 The Board Of Regents Of The University Of Oklahoma Method of lightening skin
ES2237415T5 (es) * 1999-01-14 2008-12-16 Noven Pharmaceuticals, Inc. Composiciones dermicas.
US20030170195A1 (en) 2000-01-10 2003-09-11 Noven Pharmaceuticals, Inc. Compositions and methods for drug delivery
ATE290856T1 (de) * 1999-12-16 2005-04-15 Dermatrends Inc Hydroxide freisetzende verbindungen zum verbessern der hautdurchlässigkeit
JP3962684B2 (ja) * 2000-11-06 2007-08-22 サムヤン コーポレイション 改善された水分吸収能および接着性を有する経皮投与剤
US8217157B2 (en) * 2003-05-19 2012-07-10 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof
WO2005009510A2 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
US20050209295A1 (en) * 2004-03-16 2005-09-22 Kohn Leonard D Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
FR2873883B1 (fr) * 2004-07-28 2006-09-29 Sagem Procede de tramage d'une image
CA2617934A1 (en) 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation
NZ552816A (en) 2007-01-24 2009-05-31 Bomac Research Ltd Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122472A1 (fr) * 2005-05-18 2006-11-23 Ling Chen Onguent antithyroïdien à usage externe et préparation de celui-ci

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOFFMAN, G. ET AL: J. Feline Medicine and Surgery. 2003, 5:77-82. *
HOFFMAN, S. B. ET AL: J vet. Pharmacol. Therap. 2002, 25:189-193. *

Also Published As

Publication number Publication date
CA2713199A1 (en) 2008-07-31
EP2124938A1 (en) 2009-12-02
CA2713199C (en) 2015-05-19
NZ552816A (en) 2009-05-31
AU2008208151A1 (en) 2008-07-31
US8748467B2 (en) 2014-06-10
WO2008091167A1 (en) 2008-07-31
JP2010516761A (ja) 2010-05-20
US20100137389A1 (en) 2010-06-03
EP2124938A4 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
US12403091B2 (en) Delivery system
US20210177782A1 (en) High concentration local anesthetic formulations
EP2293777B1 (en) Pharmaceutical transdermal compositions and method for treating inflammation in cattle
EP2120860B1 (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals
AU2008208151B2 (en) Topical formulation
JP7752051B2 (ja) 長時間作用型注射用製剤およびその使用
RS62055B1 (sr) Stimulacija apetita, upravljanje gubitkom težine i lečenje anoreksije kod pasa i mačaka
US11058629B2 (en) Long-acting non-aqueous injectable formulations and use thereof
US20240207206A1 (en) Improved Topical Composition of Colchicine
ES2617672T3 (es) Composiciones antihelmínticas de bencimidazol
CN114939104A (zh) 一种用于减轻猫应激的外用透皮制剂、制备方法及应用
EP3908255B1 (en) Stable topical compositions of fenoldopam
CA2946434C (en) Transdermal formulations of pergolide and uses thereof
EP4389147A2 (en) Therapeutic formulations and uses thereof
JP2025186498A (ja) 長時間作用型注射用製剤およびその使用
US20250381136A1 (en) Delivery system

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ELANCO NEW ZEALAND

Free format text: FORMER OWNER(S): BAYER NEW ZEALAND LIMITED